1. HBW Insight
  2. >>Health

Federal Preemption Strikes California Prop 65 Complaint Against Generic OTC Ranitidine Firms

Case Against Zantac Marketer Could Strike Out On Faulty Research Behind Carcinogen Claim

 
• By Malcolm Spicer

Whether California court finds Zantac, when marketed containing ranitidine, should have had a Prop 65 label warning could be influenced by dismissal in federal court of class action complaints due to faulty research behind claims that ranitidine causes a carcinogenic substance to form post-production.  

• Source: Shutterstock

Federal preemption relieves manufacturers of OTC generic ranitidine heartburn remedies of obligation to use Proposition 65 label warnings in California as alleged in a complaint, according to a state appeals court.

The same relief, but for a different reason could come for the firm previously marketing the OTC Zantac (150-mg ranitidine) brand

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal

More from Policy & Regulation